SCHEMBL6005627

SCHEMBL6005627

CC(C)(Cc1ccc(Cl)cc1Cl)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GGPS1 O95749 1/20 0.54
NPC1 O15118 1/20 0.47
ACLY P53396 2/20 0.46
NR4A2 P43354 1/20 0.44
IDO1 P14902 1/20 0.44
KDM4E B2RXH2 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
TSHR P16473 1/20 0.43
CASP1 P29466 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
SLC16A3 O15427 1/20 0.43
SLC16A1 P53985 1/20 0.43
MCTS1 Q9ULC4 1/20 0.43
EPHX1 P07099 1/20 0.42
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10470120 0.86 GGPS1 (0.54) GGPS1NPC1NR4A2IDO1KDM4E
SCHEMBL16302165 0.83 ACLY (0.53) NPC1ACLY
SCHEMBL10470826 0.82 GGPS1 (0.50) GGPS1NPC1NR4A2IDO1KDM4E
SCHEMBL15814208 0.80 KDM4E (0.42) KDM4EL3MBTL1CYP1A2CYP3A4CYP2C9
SCHEMBL3030149 0.78 GGPS1 (0.56) GGPS1NPC1IDO1CYP1A2CYP3A4
SCHEMBL3030151 0.78 GGPS1 (0.56) GGPS1NPC1IDO1CYP1A2CYP3A4
SCHEMBL6886022 0.77 GGPS1 (0.55) GGPS1IDO1KDM4ECYP1A2CYP3A4
SCHEMBL10891005 0.76 NR4A2 (0.49) GGPS1NPC1NR4A2KDM4EL3MBTL1
SCHEMBL10580138 0.76 GGPS1 (0.44) GGPS1NPC1L3MBTL1MAPK1EPHX1
SCHEMBL17513393 0.75 IDO1 (0.44) GGPS1NPC1ACLYNR4A2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105509-B2 Benzodiazepine derivatives as APP modulators MERCK SHARP & DOHME LIMITED (GB) 2006-09-12 US disclosed
US-20040082572-A1 Benzodiazepine derivatives as app modulators MERCK SHARPE & DOHME LIMITED (GB) 2004-04-29 US disclosed
EP-1294702-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LTD. (GB) 2003-03-26 EP disclosed
WO-2001090084-A1 BENZODIAZEPINE DERIVATIVES AS APP MODULATORS MERCK SHARP & DOHME LIMITED (GB) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082572-A1 Benzodiazepine derivatives as app modulators BACE1, PSEN1, APP GGPS1 2170/4885NPC1 461/4885ACLY 3824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.